Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced that NXP002, a new form of tranilast and a potential novel inhaled treatment for Idiopathic Pulmonary Fibrosis, has successfully completed pre-clinical tolerability studies for a new NXP002 formulation.
As announced on 27 June 2022, the Company initiated further pre-clinical studies as it continues to generate a robust data package to support the progression of NXP002. Tolerability has been demonstrated across a new range of doses, including higher doses than previously given, delivered using an alternative method designed to ensure that consistent and controlled inhalation exposure is achieved.
Work has now commenced to explore how the new doses studied can best optimise efficacy and confirm NXP002’s positive pharmacological profile towards the treatment of lung fibrosis and inflammation via inhalation, before progression to a final step to assess duration of action. Results will continue to be generated throughout H2 2022 and further updates will be announced in due course.
Dr Daniel Gooding, Executive Director of Nuformix, commented: “The results from this first stage are exactly what we had hoped for and bode well for the inhaled tolerability of NXP002, even at high doses. We are pleased that we can now progress to robustly investigate NXP002’s efficacy as we continue to build a pre-clinical data package to support the further progression of the Company’s lead programme. I look forward to providing further updates to the market when appropriate.”